Abstract
The development of genetic and serological markers of autoimmune Type I diabetes has allowed us to begin to identify subjects at risk for the development of Type I diabetes. Assessment of these variables can assign risk to subjects and permit the implementation of immune intervention trials in an attempt to alter the course of pre-diabetes. This review discusses relevant aspects of the genetics and diagnosis of pre-diabetes, and both current and future clinical trials that are attempting to prevent the full expression of clinical diabetes in these individuals.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Autoantibodies / blood
-
Autoimmune Diseases / blood
-
Autoimmune Diseases / diagnosis*
-
Autoimmune Diseases / genetics
-
Autoimmune Diseases / prevention & control
-
Autoimmune Diseases / therapy
-
Biomarkers / blood
-
Clinical Trials as Topic
-
Diabetes Mellitus, Type 1 / blood
-
Diabetes Mellitus, Type 1 / diagnosis*
-
Diabetes Mellitus, Type 1 / genetics
-
Diabetes Mellitus, Type 1 / immunology
-
Diabetes Mellitus, Type 1 / prevention & control
-
Diabetes Mellitus, Type 1 / therapy
-
Forecasting
-
Gene Expression
-
Genetic Markers
-
Humans
-
Immunotherapy
-
Prediabetic State / blood
-
Prediabetic State / diagnosis*
-
Prediabetic State / genetics
-
Prediabetic State / immunology
-
Prediabetic State / prevention & control
-
Prediabetic State / therapy
-
Risk Factors
Substances
-
Autoantibodies
-
Biomarkers
-
Genetic Markers